Kevin David Costa
Corporate Officer/Principal bij Icahn School of Medicine at Mount Sinai
Actieve functies van Kevin David Costa
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | 01-01-2009 | - |
Loopbaan van Kevin David Costa
Eerdere bekende functies van Kevin David Costa
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | - | - |
| NOVOHEART HOLDINGS INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 | - |
| Oprichter | 28-04-1964 | - |
Opleiding van Kevin David Costa
| Boston University | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Canada | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoraal
| Consumer Services | 5 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Novoheart Holdings, Inc.
 Novoheart Holdings, Inc. BiotechnologyHealth Technology Novoheart Holdings, Inc. is a global stem cell biotechnology company. It engages in engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardio toxicity screening, diseases modeling and therapeutic applications. The firm products include Human Ventricular Cardiomyocytes (hvCM), Cardiac Anisotropic Sheet (hvCAS), Cardiac Anisotropic Patch (hvCAP), Cardiac Tissue Strip (hvCTS), and novoHeart. The company was founded by Michelle Khine, Kevin Costa and Ronald Li on April 28, 1964 and is headquartered in Vancouver, Canada. | Health Technology |
- Beurs
- Insiders
- Kevin David Costa
- Ervaring
